MCRB Seres Therapeutics, Inc.

10.18
+0  (4%)
Previous Close 9.76
Open 9.80
Price To book 2.97
Market Cap 410.95M
Shares 40,368,000
Volume 164,814
Short Ratio 22.53
Av. Daily Volume 249,750

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b initiated July 2016. Data due 2017
SER-262
Primary Clostridium Difficile infection (CDI)
Phase 2 interim data did not meet primary endpoint. Additional Phase 2 trial to be initiated.
SER-109
Recurrent C. Difficile infection
Phase 1b initiated December 2015. Enrolment ongoing as of May 2016. Data due 2017.
SER-287
Mild-to-Moderate Ulcerative Colitis

Latest News

  1. Seres Therapeutics, Inc. – Value Analysis (NASDAQ:MCRB) : April 19, 2017
  2. Seres Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MCRB-US : April 18, 2017
  3. Seres Therapeutics Inc (MCRB) Announces New “Poop Pill” Phase 2 Study
  4. Edited Transcript of MCRB earnings conference call or presentation 16-Mar-17 12:00pm GMT
  5. Why GoPro, Barnes & Noble, and Seres Therapeutics Jumped Today
  6. Here's What's Lifting Seres Therapeutics Inc.'s Stock Price Today
  7. Biotech Premarket Movers: Seres, PTC, Inovio
  8. Seres gets FDA mulligan on microbiome drug, eyes pivotal trial
  9. Seres Therapeutics to Initiate New SER-109 Clinical Study
  10. Seres Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Operational Progress Update
  11. Seres Therapeutics to Host Fourth Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on March 16, 2017
  12. Seres Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference
  13. Why Seres Therapeutics (MCRB) Might Surprise This Earnings Season
  14. Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences
  15. Seres Therapeutics (MCRB) Rises: Stock Adds 5% in Session
  16. Seres finally explains 'poop pill' failure, reassuring investors
  17. Seres Therapeutics Announces Key Findings from SER-109 Phase 2 Study Analyses
  18. Seres Therapeutics to Host Conference Call and Webcast to Announce Key Findings from SER-109 Phase 2 Study Analyses
  19. Seres Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MCRB-US : January 18, 2017
  20. Seres Therapeutics, Inc. – Value Analysis (NASDAQ:MCRB) : January 6, 2017